KCT0006857已完成未知
A randomized, double-blind, control food (Placebo) comparative clinical trial to evaluate the functionality and safety of BEX for reducing body fat in overweight or obese adults
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 60(Year)（—）
- 性别
- All
入选标准
- •1) Men and women between the ages of 19 and 60
- •2) Subjects with a body mass index (BMI) of 25 kg/m2 or more and less than 30 kg/m2
- •3) Subjects who consented to participate in this study and voluntarily signed a written consent form
排除标准
- •1) Subjects with severe cerebrovascular disease (cerebral infarction, cerebral hemorrhage, etc.), heart disease (angina, myocardial infarction, heart failure, arrhythmia requiring treatment), or malignant tumor within the last 6 months (however, cerebrovascular disease, heart disease) Subjects who have a medical history but are clinically stable may participate in the trial at the discretion of the investigator.)
- •2) Drugs that affect body weight (fat absorption inhibitors and appetite suppressants, health food/supplements related to obesity, psychiatric drugs such as depression, beta blockers, diuretics, contraceptives, steroids, female hormones) within the last 1 month subject who is taking
- •3) Obese or overweight subjects due to endocrine diseases such as hypothyroidism and Cushing's syndrome
- •4) Subjects who are continuously receiving treatment or taking medications for gastrointestinal disorders (gastric ulcer, chronic digestive disorder, irritable bowel syndrome, etc.)
- •5) Subjects with a psychologically significant medical history or current disease (schizophrenia, epilepsy, anorexia, bulimia, etc.), or a history of alcohol and other drug abuse
- •6) Subjects judged to be unable to exercise due to musculoskeletal disorders
- •7) Fasting blood sugar of 126 mg/dl or more, random blood sugar of 200 mg/dl or more, or diabetic patients taking oral hypoglycemic agents or insulin
- •8) Patients with uncontrolled hypertension (blood pressure greater than 160/100 mmHg, measured after subject resting for 10 minutes)
- •9) Subjects whose AST(GOT) or ALT(GPT) is 2.5 times or more of the laboratory's upper limit of normal
- •10) Subjects with more than twice the upper limit of normal creatinine testing institute
- •11) Subjects who have lost 5% or more of weight within the last 3 months
- •12) Subjects who have participated in a commercial obesity program within the last 3 months
- •13) Subjects for whom 6 months have not elapsed since participating in the same trial
- •14) Subjects who are pregnant, lactating, or planning to become pregnant during the human application test period
- •15) Subjects who have an allergic reaction to food for human application testing
- •16) Subjects who are judged to be inappropriate as a researcher for other reasons
研究者
相似试验
招募中
4 期
A randomized, double-blinded, controlled trial of adding a short burst of corticosteroid to the conventional treatment of H1 antihistaminesPatients visit emergency room at King chulalongkorn memorial hospital (KCMH) Age between 18ᇆ years Pateint who meet the following criteria of acute urticarialAcute urticaria,Emergency department,Out-patient,Allergic reaction,Antihistamines,Steroids,Acute allergic syndrome,H1-Corticosteroid,Chronic urticariaTCTR20180321001Rachada69
已完成
不适用
A prospective , double blind, randomised controlled trial evaluating the effects of mitomycin C on postoperative healing following endoscopic sinus surgery (ESS) to the frontonasal recess.ISRCTN42522811Record Provided by the NHSTCT Register - 2005 Update - Department of Health (UK)20
已完成
不适用
To determine the effects of Oxystorm pre-workout as compared to placebo on endurance and muscular strength, perceived energy and aerobic fitness performance in healthy adult malesCTRI/2016/06/007017Arjuna Natural Extracts Ltd12
已完成
不适用
swallow's nest extract clinical trialDiseases of the skin and subcutaneous tissueKCT0006558Semyung University104
已完成
3 期
clinical study of Diabetic Support Product in Subjects suffering from Type II DiabetesCTRI/2022/01/039179Mr Kamlesh Thummar156